Monz takes over as ceo of Carl Zeiss Meditec

Ludwin Monz has been named as chief executive of Carl Zeiss Meditec.

Ludwin Monz has been named as chief executive of Carl Zeiss Meditec. He takes over from Michael Kaschke, who resumes his role as chairman of the company's supervisory board.

Monz has been a member of Carl Zeiss Meditec's management board since October 2007 and is responsible for the firm's Ophthalmological Systems division. Prior to this he led the Microsurgery division for six years.

With a doctorate in physics and an MBA, Monz joined the Carl Zeiss Group in 1994 and has worked in medical technology since 2000.

You may also like

Digital

Shimadzu introduces a new site for its portfolio of LIB solutions

The website especially targets battery cell manufacturers, e-vehicle OEMs, research institutions as well as recycling companies and start-ups. There they will find Shimadzu’s latest solutions in the LIB market, including in-depth background information such as brochures and FAQs as well as featured highlight products
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Sustainability

Veeva launches eSource application to eliminate paper and streamline clinical trial data flow

Frees research sites from duplicate data entry and connects EHR and EDC for higher quality trial data, faster
Digital

Medical device manufacturer bridges the IT/OT gap

Learn how a large pharmaceutical and medical device manufacturer secured their OT networks with SecureOT Platform
Digital

Mitsubishi Electric training strengthens FDA Packaging’s automation capabilities

Hands-on PLC training helps UK flow wrapping machine builder transition to intuitive GX Works3 software, boosting efficiency and future scalability
Digital

Beyond the portal: building the digital foundations for global CGT delivery

As 2025 unfolds and planning for 2026 gathers momentum, manufacturers face a landscape in which supply chain uncertainty, sustainability demands and digital transformation are reshaping priorities
Digital

Pharma in 2025–2026: AI, China and the new era of drug development

In 2025, the pace of change throughout chemical and pharmaceutical manufacturing is accelerating, creating a complex mix of emerging opportunities and structural challenges that will define the year ahead
Subscribe now